enobosarm
enobosarm: developed by 1 company · 2 clinical trials tracked.
enobosarm evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could enobosarm → VERU affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| VERU INC. (VERU) Muscle Loss; Obesity & Overweight | Phase 2 |
Clinical Trials (2)
PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction
Primary endpoint: To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.
A Phase 2 Dose-Finding and Proof-of-Concept Study to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management
Primary endpoint: The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.
Frequently asked questions
Who is developing enobosarm?
enobosarm is being developed by VERU INC..
How many clinical trials involve enobosarm?
BioSniper tracks 2 clinical trials involving enobosarm.